A Phase 3 interventional study of Oxaliplatin Based Chemotherapy and Panitumumab in Colorectal Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.
Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 4th largest by enrollment of the 88 interventional ones that give a count, is the only one that started in 2005, is one of 14 in phase 3, and was the 9th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
AbbVie · Sites in United States, Australia, Austria and 12 more countries
Ages 18+
R-Pharm · Sites in Russia
Ages 18+
UNICANCER · Sites in France
Ages 18+
Amgen · Sites in United States, Argentina, Australia and 32 more countries
Ages 18+
By country, each count listing its studies:
Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 68 · Phase 3 15 · Phase 4 1
First in 2000; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,053 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 70 across the 88 interventional studies. Of the 67 that completed or were terminated, 30 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 90 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
40 studies in Colorectal Neoplasms by Amgen: 2 open now, 2 under way, 1 of them phase 3. Of 38 finished, 24 (63%) have results posted.
Among the 40 studies in Colorectal Neoplasms by Amgen, this one is the 3rd largest by enrollment of the 33 interventional ones that give a count, is the only one that started in 2005, is one of 10 in phase 3, and was the 8th registered.
Amgen’s Colorectal Neoplasms studies by the year they started, since 2002.
3 of the studies testing panitumumab in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03087071M.D. Anderson Cancer CenterPanitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | 2027-01-31 |
| NCT05845450Gruppo Oncologico del Nord-OvestPre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | 2027-05 |
| NCT07318389M.D. Anderson Cancer CenterASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | 2027-11-14 |
Add all 3 to your calendar (.ics) → With an account.
Among the 90 studies testing panitumumab in Colorectal Neoplasms, from their registry updates:
Among Amgen’s 40 in Colorectal Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess whether treatment with the study drug, panitumumab given concomitantly with every 2 (Q2) week oxaliplatin-based chemotherapy and bevacizumab improves progression-free survival (PFS) compared to treatment Q2-week with oxaliplatin-based chemotherapy and bevacizumab alone. All subjects will receive Q2-week oxaliplatin- or irinotecan-based chemotherapy and bevacizumab. Control arm subjects will not receive concomitant panitumumab therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If history of other primary cancer, subject will be eligible only if she or he has:
Adequate hematologic data as follows:
Adequate hepatic function:
Exclusion Criteria:
Any of the following within 1 year before randomization:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone.
Drug: Oxaliplatin Based Chemotherapy · Drug: Bevacizumab
Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6mg/kg Q2W
Drug: Panitumumab · Drug: Irinotecan Based Chemotherapy · Drug: Bevacizumab
Irinotecan-based chemotherapy and Bevacizumab Q2W alone
Drug: Irinotecan Based Chemotherapy · Drug: Bevacizumab
Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6mg/kg Q2W
Drug: Oxaliplatin Based Chemotherapy · Drug: Panitumumab · Drug: Bevacizumab
Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
Also known as: FOLFOX 4, FOLFOX 5, Modified FOLFOX 6, FOLFOX 7, Oxaliplatin
PanitumumabPanitumumab is a high affinity (Kd = 5 x 10-11 M) fully human IgG2 monoclonal antibody that is directed against the human EGFr. Panitumumab will be administered by a 30-60 minute IV infusion at a dose of 6 mg/kg once every 2 weeks on the same day of the oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.
Also known as: pmab, Vectibix
Irinotecan-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) - Irinotecan, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
Also known as: FOLFIRI, Douillard
Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .
Also known as: Avastin
Progression-Free Survival (Oxaliplatin)
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression
Time frame: Overall study
Objective Tumor Response Through Week 12 (Irinotecan)
Objective tumor response (complete or partial) rate through week 12 based on central review in the Irinotecan stratum
Time frame: Overall Study
Overall Survival (Oxaliplatin)
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin
Time frame: Overall study
Objective Tumor Response Rate (Oxaliplatin)
Best overall response of complete or partial response within oxaliplatin stratum
Time frame: Overall study
Time to Progression (Oxaliplatin)
Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the oxaliplatin stratum
Time frame: Overall Study
Time to Treatment Failure (Oxaliplatin)
Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the oxaliplatin stratum.
Time frame: Overall study
Overall Survival (Irinotecan)
Incidence of mortality from any cause in groups treated with Irinotecan. Incidence is provided in lieu of the median time to death since the median or its measure of dispersion was not estimable for at least one treatment arm.
Time frame: Overall study
Progression-free Survival (Irinotecan)
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression
Time frame: Overall Study
Objective Tumor Response Rate (Irinotecan)
Best overall response of complete or partial response within irinotecan stratum
Time frame: Overall Study
Time to Progression (Irinotecan)
Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the irinotecan stratum
Time frame: Overall Study
Time to Treatment Failure (Irinotecan)
Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the irinotecan stratum
Time frame: Overall Study
Participants were enrolled from 10 March 2005 through 19 October 2006.
| Milestone | Irinotecan and Bevacizumab Without Panitumumab | Oxaliplatin and Bevacizumab Plus Panitumumab | Oxaliplatin and Bevacizumab Without Panitumumab | Irinotecan and Bevacizumab Plus Panitumumab |
|---|---|---|---|---|
| Started | 115 | 413 | 410 | 115 |
| Completed | 80 | 313 | 289 | 84 |
| Not completed | 35 | 100 | 121 | 31 |
| Withdrew: Withdrawal by subject | 22 | 53 | 76 | 15 |
| Withdrew: Physician decision | 4 | 15 | 18 | 13 |
| Withdrew: Lost to follow-up | 3 | 20 | 18 | 1 |
| Withdrew: Other | 6 | 12 | 9 | 2 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression
| Month | Oxaliplatin and Bevacizumab Plus Panitumumab | Oxaliplatin and Bevacizumab Without Panitumumab |
|---|---|---|
| Progression-Free Survival (Oxaliplatin) | 10.0 (8.9 to 11.0) | 11.4 (10.5 to 11.9) |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin
| Month | Oxaliplatin and Bevacizumab Plus Panitumumab | Oxaliplatin and Bevacizumab Without Panitumumab |
|---|---|---|
| Overall Survival (Oxaliplatin) | 19.4 (18.4 to 20.8) | 24.5 (20.4 to 24.5) |
Best overall response of complete or partial response within oxaliplatin stratum
| Participant | Oxaliplatin and Bevacizumab Plus Panitumumab | Oxaliplatin and Bevacizumab Without Panitumumab |
|---|---|---|
| Objective Tumor Response Rate (Oxaliplatin) | 190 | 196 |
Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the oxaliplatin stratum
| Month | Oxaliplatin and Bevacizumab Plus Panitumumab | Oxaliplatin and Bevacizumab Without Panitumumab |
|---|---|---|
| Time to Progression (Oxaliplatin) | 10.8 (9.5 to 11.3) | 11.4 (10.9 to 12.2) |
Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the oxaliplatin stratum.
| Month | Oxaliplatin and Bevacizumab Plus Panitumumab | Oxaliplatin and Bevacizumab Without Panitumumab |
|---|---|---|
| Time to Treatment Failure (Oxaliplatin) | 5.7 (5.5 to 6.0) | 5.9 (5.7 to 6.2) |
Objective tumor response (complete or partial) rate through week 12 based on central review in the Irinotecan stratum
| Participant | Irinotecan and Bevacizumab Plus Panitumumab | Irinotecan and Bevacizumab Without Panitumumab |
|---|---|---|
| Objective Tumor Response Through Week 12 (Irinotecan) | 29 | 27 |
Incidence of mortality from any cause in groups treated with Irinotecan. Incidence is provided in lieu of the median time to death since the median or its measure of dispersion was not estimable for at least one treatment arm.
| Participant | Irinotecan and Bevacizumab Plus Panitumumab | Irinotecan and Bevacizumab Without Panitumumab |
|---|---|---|
| Overall Survival (Irinotecan) | 26 | 18 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression
| Month | Irinotecan and Bevacizumab Plus Panitumumab | Irinotecan and Bevacizumab Without Panitumumab |
|---|---|---|
| Progression-free Survival (Irinotecan) | 10.1 (8.2 to 13.7) | 11.7 (9.0 to 13.2) |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS)
| Month | Oxaliplatin and Bevacizumab Plus Panitumumab | Oxaliplatin and Bevacizumab Without Panitumumab |
|---|---|---|
| Progression-free Survival (Wild-type KRAS) | 9.8 (8.4 to 11.3) | 11.5 (10.6 to 12.3) |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS)
| Month | Oxaliplatin and Bevacizumab Plus Panitumumab | Oxaliplatin and Bevacizumab Without Panitumumab |
|---|---|---|
| Progression-free Survival (Mutant KRAS) | 10.4 (9.1 to 11.3) | 11.0 (9.9 to 12.8) |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median
| Participant | Oxaliplatin and Bevacizumab Plus Panitumumab | Oxaliplatin and Bevacizumab Without Panitumumab |
|---|---|---|
| Overall Survival (Wild-type KRAS) | 71 | 46 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median.
| Participant | Oxaliplatin and Bevacizumab Plus Panitumumab | Oxaliplatin and Bevacizumab Without Panitumumab |
|---|---|---|
| Overall Survival (Mutant KRAS) | 47 | 45 |
Best overall response of complete or partial response in participants treated with irinotecan and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS)
| Participant | Irinotecan and Bevacizumab Plus Panitumumab | Irinotecan and Bevacizumab Without Panitumumab |
|---|---|---|
| Objective Tumor Response Rate (Wild-type KRAS) | 31 | 28 |
Best overall response of complete or partial response in participants treated with irinotecan and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS)
| Participant | Irinotecan and Bevacizumab Plus Panitumumab | Irinotecan and Bevacizumab Without Panitumumab |
|---|---|---|
| Objective Tumor Response Rate (Mutant KRAS) | 14 | 15 |
Best overall response of complete or partial response within irinotecan stratum
| Participant | Irinotecan and Bevacizumab Plus Panitumumab | Irinotecan and Bevacizumab Without Panitumumab |
|---|---|---|
| Objective Tumor Response Rate (Irinotecan) | 49 | 46 |
Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the irinotecan stratum
| Month | Irinotecan and Bevacizumab Plus Panitumumab | Irinotecan and Bevacizumab Without Panitumumab |
|---|---|---|
| Time to Progression (Irinotecan) | 11.1 (8.3 to 14.1) | 11.9 (9.0 to 13.2) |
Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the irinotecan stratum
| Month | Irinotecan and Bevacizumab Plus Panitumumab | Irinotecan and Bevacizumab Without Panitumumab |
|---|---|---|
| Time to Treatment Failure (Irinotecan) | 6.6 (5.9 to 8.0) | 6.0 (4.8 to 6.9) |
Collected over First dose through maximum of safety FU or 30 days after last dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panit. Plus Bevacizumab With Chemotherapy | — | 306/518 (59.1%) | 516/518 (99.6%) |
| Bevacizumab With Chemotherapy | — | 188/510 (36.9%) | 505/510 (99%) |
| Event | Panit. Plus Bevacizumab With Chemotherapy | Bevacizumab With Chemotherapy |
|---|---|---|
| DEHYDRATIONMetabolism and nutrition disorders | 72/518 | 21/510 |
| DIARRHOEAGastrointestinal disorders | 63/518 | 15/510 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 35/518 | 17/510 |
| VOMITINGGastrointestinal disorders | 27/518 | 10/510 |
| NAUSEAGastrointestinal disorders | 24/518 | 7/510 |
| ABDOMINAL PAINGastrointestinal disorders | 23/518 | 17/510 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 20/518 | 9/510 |
| DEEP VEIN THROMBOSISVascular disorders | 17/518 | 12/510 |
| PYREXIAGeneral disorders | 16/518 | 9/510 |
| SEPSISInfections and infestations | 16/518 | 8/510 |
| Event | Panit. Plus Bevacizumab With Chemotherapy | Bevacizumab With Chemotherapy |
|---|---|---|
| DIARRHOEAGastrointestinal disorders | 385/518 | 350/510 |
| FATIGUEGeneral disorders | 354/518 | 371/510 |
| NAUSEAGastrointestinal disorders | 359/518 | 368/510 |
| RASHSkin and subcutaneous tissue disorders | 331/518 | 71/510 |
| CONSTIPATIONGastrointestinal disorders | 217/518 | 187/510 |
| VOMITINGGastrointestinal disorders | 215/518 | 199/510 |
| ANOREXIAMetabolism and nutrition disorders | 211/518 | 155/510 |
| NEUTROPENIABlood and lymphatic system disorders | 179/518 | 207/510 |
| DERMATITIS ACNEIFORMSkin and subcutaneous tissue disorders | 179/518 | 7/510 |
| ANAEMIABlood and lymphatic system disorders | 177/518 | 147/510 |
| Age, Continuous(Year) | Oxaliplatin and Bevacizumab Without Panitumumab | Irinotecan and Bevacizumab Plus Panitumumab | Irinotecan and Bevacizumab Without Panitumumab | Oxaliplatin and Bevacizumab Plus Panitumumab | Total |
|---|---|---|---|---|---|
| Mean | 61.0 ± 11.9 | 59.4 ± 11.7 | 57.8 ± 12.0 | 60.8 ± 11.7 | 60.4 ± 11.8 |
| Sex: Female, Male(Participants) | Oxaliplatin and Bevacizumab Without Panitumumab | Irinotecan and Bevacizumab Plus Panitumumab | Irinotecan and Bevacizumab Without Panitumumab | Oxaliplatin and Bevacizumab Plus Panitumumab | Total |
|---|---|---|---|---|---|
| Female | 172 | 59 | 44 | 180 | 455 |
| Male | 238 | 56 | 71 | 233 | 598 |
| Race/Ethnicity, Customized(Participant) | Oxaliplatin and Bevacizumab Without Panitumumab | Irinotecan and Bevacizumab Plus Panitumumab | Irinotecan and Bevacizumab Without Panitumumab | Oxaliplatin and Bevacizumab Plus Panitumumab | Total |
|---|---|---|---|---|---|
| White or Caucasian | 330 | 86 | 85 | 343 | 844 |
| Black or African American | 41 | 18 | 16 | 35 | 110 |
| Hispanic or Latino | 25 | 6 | 14 | 25 | 70 |
| Asian | 10 | 2 | 0 | 10 | 22 |
| Japanese | 2 | 0 | 0 | 0 | 2 |
| American Indian or Alaska Native | 1 | 2 | 0 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| Other | 0 | 1 | 0 | 0 | 1 |
| ECOG Score(Participant) | Oxaliplatin and Bevacizumab Without Panitumumab | Irinotecan and Bevacizumab Plus Panitumumab | Irinotecan and Bevacizumab Without Panitumumab | Oxaliplatin and Bevacizumab Plus Panitumumab | Total |
|---|---|---|---|---|---|
| 0 | 239 | 68 | 74 | 253 | 634 |
| 1 | 171 | 47 | 41 | 160 | 419 |
| Number of Metastatic Organs(Participant) | Oxaliplatin and Bevacizumab Without Panitumumab | Irinotecan and Bevacizumab Plus Panitumumab | Irinotecan and Bevacizumab Without Panitumumab | Oxaliplatin and Bevacizumab Plus Panitumumab | Total |
|---|---|---|---|---|---|
| None | 0 | 0 | 0 | 1 | 1 |
| 1 | 199 | 46 | 53 | 204 | 502 |
| >1 | 211 | 69 | 62 | 208 | 550 |
| Primary Site of Disease(Participant) | Oxaliplatin and Bevacizumab Without Panitumumab | Irinotecan and Bevacizumab Plus Panitumumab | Irinotecan and Bevacizumab Without Panitumumab | Oxaliplatin and Bevacizumab Plus Panitumumab | Total |
|---|---|---|---|---|---|
| Colon | 326 | 92 | 95 | 322 | 835 |
| Rectal | 84 | 23 | 20 | 91 | 218 |
| Prior adjuvant chemotherapy(Participant) | Oxaliplatin and Bevacizumab Without Panitumumab | Irinotecan and Bevacizumab Plus Panitumumab | Irinotecan and Bevacizumab Without Panitumumab | Oxaliplatin and Bevacizumab Plus Panitumumab | Total |
|---|---|---|---|---|---|
| Yes | 77 | 38 | 36 | 80 | 231 |
| No | 333 | 77 | 79 | 333 | 822 |
No study locations are listed for this record.
Ran from Jun 2005 to primary completion in May 2007, 23 months.
Results were first posted in Sep 2010, 3 years 3 months after primary completion.
Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 23 months is below that.
Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Panitumumab